Evidence map›Paper›PMID 35546268›Full record

ArticleCephalalgia : an international journal of headache2022

Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.

Edita Navratilova, Janice Oyarzo, Trent Anderson, Ron S Broide, Sudhakar R Subramaniam, Edwin J Vazquez-Cintron, Mitchell F Brin, Todd J Schwedt, David W Dodick, Frank Porreca

Open access · hybridAbstract read
In one paragraph

Article in Cephalalgia : an international journal of headache, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Edita NavratilovaDepartment of Pharmacology, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA.ORCID 0000-0002-1497-125X
Janice OyarzoMayo Clinic, Scottsdale, AZ, USA.
Trent AndersonDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ, USA.
Ron S BroideAllergan Aesthetics, an AbbVie Company, USA.
Sudhakar R SubramaniamAllergan Aesthetics, an AbbVie Company, USA.
Edwin J Vazquez-CintronAllergan Aesthetics, an AbbVie Company, USA.
Mitchell F BrinAllergan Aesthetics, an AbbVie Company, USA.ORCID 0000-0002-1989-6076
Todd J SchwedtMayo Clinic, Scottsdale, AZ, USA.
David W DodickMayo Clinic, Scottsdale, AZ, USA.
Frank PorrecaDepartment of Pharmacology, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA.
AbbVie (United States) · USMayo Clinic in Arizona · USUniversity of Arizona · USUniversity of California, Irvine · US

Funding

Mechanisms and Therapeutic Strategies for Post-traumatic HeadacheR01NS114888 · NINDS · UNIVERSITY OF ARIZONA · PI ANDERSON, TRENT, NAVRATILOVA, EDITA · 2020 to 2024
$2.4M
NINDS NIH HHS R01 NS114888
6 · The paper itself

Abstract

objectiveInvestigation of onabotulinumtoxinA in a murine model of acute and persistent post-traumatic headache.

methodsMild traumatic brain injury was induced with a weight drop method. Periorbital and hindpaw cutaneous allodynia were measured for 14 days. Mice were then exposed to bright light stress and allodynia was reassessed. OnabotulinumtoxinA (0.5 U) was injected subcutaneously over the cranial sutures at different post-injury time points.

resultsAfter milt traumatic brain injury, mice exhibited periorbital and hindpaw allodynia that lasted for approximately 14 days. Allodynia could be reinstated on days 14-67 by exposure to stress only in previously injured mice. OnabotulinumtoxinA administration at 2 h after mild traumatic brain injury fully blocked both transient acute and stress-induced allodynia up to day 67. When administered 72 h post-mild traumatic brain injury, onabotulinumtoxinA reversed acute allodynia, but only partially prevented stress-induced allodynia. OnabotulinumtoxinA administration at day 12, when initial allodynia was largely resolved, produced incomplete and transient prevention of stress-induced allodynia. The degree of acute allodynia correlated positively with subsequent stress-induced allodynia.

conclusionMild traumatic brain injury induced transient headache-like pain followed by long lasting sensitization and persistent vulnerability to a normally innocuous stress stimulus, respectively modeling acute and persistent post-traumatic headache.. Administration of onabotulinumtoxinA following the resolution of acute post-traumatic headache diminished persistent post-traumatic headache but the effects were transient, suggesting that underlying persistent mild traumatic brain injury-induced maladaptations were not reversed. In contrast, early onabotulinumtoxinA administration fully blocked both acute post-traumatic headache as well as the transition to persistent post-traumatic headache suggesting prevention of neural adaptations that promote vulnerability to headache-like pain. Additionally, the degree of acute post-traumatic headache was predictive of risk of persistent post-traumatic headache.

Indexed as

Botulinum Toxins, Type ABrain ConcussionPost-Traumatic HeadacheTension-Type HeadacheAnimalsHeadacheHyperalgesiaMicePainBotulinum Toxins, Type Aacute post-traumatic headachebotulinum toxinconcussioncutaneous allodyniamild traumatic brain injurypersistent post-traumatic headachePost-traumatic headache

Identifiers

PMID35546268
PMCPMC9535972
OpenAlexW4280627458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.